These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 1355970)
1. Commentary on "The current status of PET scanning with respect to schizophrenia". Buchsbaum MS Neuropsychopharmacology; 1992 Aug; 7(1):67-8; discussion 73-5. PubMed ID: 1355970 [No Abstract] [Full Text] [Related]
2. PET studies of neuroreceptors in schizophrenia. Commentary on "The current status of PET scanning with respect to schizophrenia". Wong DF Neuropsychopharmacology; 1992 Aug; 7(1):69-72; discussion 73-5. PubMed ID: 1388023 [No Abstract] [Full Text] [Related]
3. Elevated D2 in schizophrenia: role of endogenous dopamine and cerebellum. Commentary on "The current status of PET scanning with respect to schizophrenia". Seeman P Neuropsychopharmacology; 1992 Aug; 7(1):55-7; discussion 73-5. PubMed ID: 1388022 [No Abstract] [Full Text] [Related]
4. PET scanning in schizophrenia, a critical evaluation. Commentary on "The current status of PET scanning with respect to schizophrenia". Murphy D; Rapoport SI Neuropsychopharmacology; 1992 Aug; 7(1):59-61; discussion 73-5. PubMed ID: 1524656 [No Abstract] [Full Text] [Related]
5. Neurotransmitters are important, but so is metabolism. Commentary on "The current status of PET scanning with respect to schizophrenia". Gur RE; Gur RC Neuropsychopharmacology; 1992 Aug; 7(1):63-5; discussion 73-5. PubMed ID: 1355969 [No Abstract] [Full Text] [Related]
6. The current status of PET scanning with respect to schizophrenia. Sedvall G Neuropsychopharmacology; 1992 Aug; 7(1):41-54. PubMed ID: 1388021 [TBL] [Abstract][Full Text] [Related]
7. In vivo neuropharmacology of schizophrenia. Bigliani V; Pilowsky LS Br J Psychiatry Suppl; 1999; (38):23-33. PubMed ID: 10884897 [No Abstract] [Full Text] [Related]
8. The significance of the D2 dopamine receptor in schizophrenia as studied with PET. Wiesel FA Clin Neuropharmacol; 1992; 15 Suppl 1 Pt A():460A-461A. PubMed ID: 1354050 [No Abstract] [Full Text] [Related]
9. Positron emission tomography--examination of chemical transmission in the living human brain. Development of radioligands. Farde L; Hall H Arzneimittelforschung; 1992 Feb; 42(2A):260-4. PubMed ID: 1316756 [TBL] [Abstract][Full Text] [Related]
10. Neurochemical imaging in schizophrenia. Urban N; Abi-Dargham A Curr Top Behav Neurosci; 2010; 4():215-42. PubMed ID: 21312402 [TBL] [Abstract][Full Text] [Related]
11. Imaging dopamine transmission in schizophrenia. A review and meta-analysis. Laruelle M Q J Nucl Med; 1998 Sep; 42(3):211-21. PubMed ID: 9796369 [TBL] [Abstract][Full Text] [Related]
12. Haloperidol blocks the uptake of [18F]N-methylspiroperidol by extrastriatal dopamine receptors in schizophrenic patients. Yousef KA; Volkow ND; Schlyer DJ; Fowler JS; Wolf AP; Wang GJ; Smith MR; Brodie JD; Warner D Synapse; 1995 Jan; 19(1):14-7. PubMed ID: 7709339 [TBL] [Abstract][Full Text] [Related]
13. In vivo assessment of dopaminergic variables in schizophrenia. Martinot JL; Paillere-Martinot ML; Lecrubier Y; Dao-Castellana MH; Loc'h C; Poirier MF; Allilaire JF; Feline A; Manus A; Aubin F Clin Neuropharmacol; 1992; 15 Suppl 1 Pt A():470A-471A. PubMed ID: 1354053 [No Abstract] [Full Text] [Related]
14. Implications of positron emission tomography research for the investigation of the actions of antipsychotic drugs. List SJ; Cleghorn JM Br J Psychiatry Suppl; 1993 Dec; (22):25-30. PubMed ID: 7906522 [TBL] [Abstract][Full Text] [Related]